Literature DB >> 14746899

A human granin-like neuroendocrine peptide precursor (proSAAS) immunoreactivity in tau inclusions of Alzheimer's disease and parkinsonism-dementia complex on Guam.

Manabu Wada1, Chang-Hong Ren, Shingo Koyama, Shigeki Arawaka, Shinobu Kawakatsu, Hideki Kimura, Hikaru Nagasawa, Toru Kawanami, Keiji Kurita, Makoto Daimon, Asao Hirano, Takeo Kato.   

Abstract

The deposition of tau inclusions is one of the neuropathological hallmarks in neurodegenerative disorders with dementia. We have reported that the N-terminal fragment of a human granin-like neuroendocrine peptide precursor (N-proSAAS) is accumulated in Pick bodies. However, it is unknown whether N-proSAAS is widely accumulated in tau inclusions in other tauopathies. Here, we performed an immunohistochemical examination using antibodies against both the N- and C-terminal sequence of proSAAS in the brains of patients with Alzheimer's disease and parkinsonism-dementia complex on Guam. The antibody against N-proSAAS immunostained neurofibrillary tangles and neuritic plaques in both diseases, whereas the antibody against the C-terminal sequence of proSAAS did not. The results of the present study suggest that N-proSAAS or proSAAS-like molecules were trapped within the tau fibrils and accumulated in tau inclusions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14746899     DOI: 10.1016/j.neulet.2003.11.028

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

Review 1.  The extended granin family: structure, function, and biomedical implications.

Authors:  Alessandro Bartolomucci; Roberta Possenti; Sushil K Mahata; Reiner Fischer-Colbrie; Y Peng Loh; Stephen R J Salton
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

2.  The neural chaperone proSAAS blocks α-synuclein fibrillation and neurotoxicity.

Authors:  Timothy S Jarvela; Hoa A Lam; Michael Helwig; Nikolai Lorenzen; Daniel E Otzen; Pamela J McLean; Nigel T Maidment; Iris Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

3.  A novel function for proSAAS as an amyloid anti-aggregant in Alzheimer's disease.

Authors:  Akina Hoshino; Michael Helwig; Sina Rezaei; Casey Berridge; Jason L Eriksen; Iris Lindberg
Journal:  J Neurochem       Date:  2013-10-24       Impact factor: 5.372

Review 4.  Chaperones in Neurodegeneration.

Authors:  Iris Lindberg; James Shorter; R Luke Wiseman; Fabrizio Chiti; Chad A Dickey; Pamela J McLean
Journal:  J Neurosci       Date:  2015-10-14       Impact factor: 6.167

5.  Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers.

Authors:  Holger Jahn; Stefan Wittke; Petra Zürbig; Thomas J Raedler; Sönke Arlt; Markus Kellmann; William Mullen; Martin Eichenlaub; Harald Mischak; Klaus Wiedemann
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

6.  Increased expression and retention of the secretory chaperone proSAAS following cell stress.

Authors:  Manita Shakya; Taha Yildirim; Iris Lindberg
Journal:  Cell Stress Chaperones       Date:  2020-07-20       Impact factor: 3.667

Review 7.  Extracellular protein components of amyloid plaques and their roles in Alzheimer's disease pathology.

Authors:  M Mahafuzur Rahman; Christofer Lendel
Journal:  Mol Neurodegener       Date:  2021-08-28       Impact factor: 14.195

Review 8.  A comprehensive systematic review of CSF proteins and peptides that define Alzheimer's disease.

Authors:  Juan R Peinado; Yoana Rabanal-Ruiz; Cristina M Pedrero-Prieto; Sonia García-Carpintero; Javier Frontiñán-Rubio; Emilio Llanos-González; Cristina Aguilera García; Francisco J Alcaín; Iris Lindberg; Mario Durán-Prado
Journal:  Clin Proteomics       Date:  2020-06-05       Impact factor: 3.988

9.  Cerebrospinal fluid proteomics implicates the granin family in Parkinson's disease.

Authors:  Melissa S Rotunno; Monica Lane; Wenfei Zhang; Pavlina Wolf; Petra Oliva; Catherine Viel; Anne-Marie Wills; Roy N Alcalay; Clemens R Scherzer; Lamya S Shihabuddin; Kate Zhang; S Pablo Sardi
Journal:  Sci Rep       Date:  2020-02-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.